Hunan Cancer Hospital
🇨🇳China
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06327698
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
Recruiting
- Conditions
- Herpesvirus 4, HumanNasopharyngeal Carcinoma
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06321939
- Locations
- 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Not yet recruiting
- Conditions
- CDK4/6 InhibitorsEndocrine TherapyBreast CancerSubsequent Treatment
- Interventions
- Drug: Different treatment regimens following progression on CDK4/6 inhibitors.
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06033287
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Completed
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 106
- Registration Number
- NCT06031376
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Clinical Study on Nutrition Intervention in Patients With Esophageal and Gastric Cancer Treated With Chemotherapy
Not Applicable
Not yet recruiting
- Conditions
- Nutrition Aspect of Cancer
- Interventions
- Dietary Supplement: Nutritional counseling，Enteral Nutrition
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT06022770
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06011330
- Locations
- 🇨🇳
Hunan Cancer Hospital, ChangSha, Hunan, China
A Real-world Study of Inetetamab for First-line Treatment of MBC
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05980208
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Completed
- Conditions
- Metastatic Colorectal Adenocarcinoma
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT05942768
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
Phase 2
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05940532
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, China
Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
Completed
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05869097
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
© Copyright 2025. All Rights Reserved by MedPath